Market capitalization | $82.48m |
Enterprise Value | $89.72m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-44.99m |
Free Cash Flow (TTM) Free Cash Flow | $-37.16m |
Cash position | $18.80m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
3 Analysts have issued a Angion Biomedica Corp forecast:
3 Analysts have issued a Angion Biomedica Corp forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.18 -1.18 |
258%
258%
|
|
EBITDA | -44 -44 |
36%
36%
|
EBIT (Operating Income) EBIT | -45 -45 |
38%
38%
|
Net Profit | -52 -52 |
64%
64%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.
Head office | United States |
CEO | Robert Connelly |
Employees | 32 |
Founded | 2011 |
Website | www.elicio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.